Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid SCHEMBL6624948 | 0.94 | TSHR (0.54) | TSHRPOLBTDP1SMN1; SMN2KMT2A | |
| SCHEMBL8433585 | 0.90 | ALDH1A1 (0.66) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL85431 | 0.86 | TSHR (0.60) | TSHRPOLBTDP1SMN1; SMN2KMT2A | |
| Hydrochloric Acid SCHEMBL5843426 | 0.85 | TSHR (0.62) | TSHRPOLBTDP1SMN1; SMN2KMT2A | |
| SCHEMBL9602488 | 0.84 | TSHR (0.58) | TSHRPOLBTDP1SMN1; SMN2KMT2A | |
| SCHEMBL23929061 | 0.84 | SMN1; SMN2 (0.82) | TSHRPOLBTDP1SMN1; SMN2KMT2A | |
| SCHEMBL3464761 | 0.84 | SMN1; SMN2 (0.59) | TSHRPOLBTDP1SMN1; SMN2KMT2A | |
| SCHEMBL5176558 | 0.84 | SMN1; SMN2 (0.59) | TSHRPOLBTDP1SMN1; SMN2KMT2A | |
| SCHEMBL3464764 | 0.84 | SMN1; SMN2 (0.59) | TSHRPOLBTDP1SMN1; SMN2KMT2A | |
| SCHEMBL1726735 | 0.83 | TSHR (0.57) | TSHRPOLBTDP1SMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109580756-A | Composition applied to Capillary Electrophoresis | 杨翠芳 | 2019-04-05 | — | — | CN | claimed |
| EP-2036895-B1 | HSP90 INHIBITOR | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2013-01-16 | — | — | EP | claimed |
| EP-1756088-A1 | QUINAZOLINE DERIVATIVES AS ERBB RECEPTOR TYROSINE KINASES | AstraZeneca AB (SE) | 2007-02-28 | — | — | EP | claimed |
| WO-2005118572-A1 | QUINAZOLINE DERIVATIVES AS ERBB RECEPTOR TYROSINE KINASES | ASTRAZENECA AB (SE) | 2005-12-15 | — | — | WO | claimed |
| US-20230113037-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-04-13 | — | — | US | disclosed |
| CN-110172051-B | IRE-1 alpha inhibitors | 复星弘创(苏州)医药科技有限公司 | 2023-03-07 | — | — | CN | disclosed |
| US-20220135552-A1 | PYRROLE DERIVATIVES AS PLK1 INHIBITORS | SENTINEL ONCOLOGY LIMITED (GB) | 2022-05-05 | — | — | US | disclosed |
| US-20210300940-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2021-09-30 | — | — | US | disclosed |
| WO-2020025517-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2020-02-06 | — | — | WO | disclosed |
| CN-110172051-A | IRE-1 alpha inhibitor | 复星弘创(苏州)医药科技有限公司 | 2019-08-27 | — | — | CN | disclosed |
| US-RE47493-E1 | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-07-09 | — | — | US | disclosed |
| CN-107082770-B | IRE-1 alpha inhibitor | 复星弘创(苏州)医药科技有限公司 | 2019-04-23 | — | — | CN | disclosed |
| WO-2008013618-A1 | PROCESS FOR PREPARING ALKYNE INTERMEDIATES FOR DENDRITIC POLYMERS | DENDRITIC NANOTECHNOLOGIES, INC. (US) | 2008-01-31 | — | — | WO | disclosed |
| US-20080004273-A1 | Inhibitors of protein tyrosine kinase activity | METHYLGENE, INC. (CA) | 2008-01-03 | — | — | US | disclosed |
| US-20070232604-A1 | receptor kinase inhibitors such as 3-(2-{4-[3-(5-tert-Butyl-isoxazol-3-yl)-ureido]-phenyl}-benzo[d]imidazo[2,1-b]thiazol-7-yl)-N-(2-morpholin-4-yl-ethyl)-propionamide; flk inhibitors | AMBIT BIOSCIENCES CORPORATION | 2007-10-04 | — | — | US | disclosed |
| US-20070213375-A1 | Triazole derivatives useful as Axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-7262182-B2 | Sulfonylethyl phosphorodiamidates | TELIK, INC. (US) | 2007-08-28 | — | — | US | disclosed |
| EP-0090063-B1 | PROCESS FOR MAKING N-(2-AMINOETHYL)AMIDES FROM OXAZOLINES AND AMINES | THE DOW CHEMICAL COMPANY (US) | 1985-09-11 | — | — | EP | disclosed |
| EP-0090063-A1 | Process for making N-(2-aminoethyl)amides from oxazolines and amines | THE DOW CHEMICAL COMPANY (US) | 1983-10-05 | — | — | EP | disclosed |
| US-4326067-A | FROM OXAZOLINE WITH AN AMINE | THE DOW CHEMICAL COMPANY (US) | 1982-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232604-A1 | receptor kinase inhibitors such as 3-(2-{4-[3-(5-tert-Butyl-isoxazol-3-yl)-ureido]-phenyl}-benzo[d]imidazo[2,1-b]thiazol-7-yl)-N-(2-morpholin-4-yl-ethyl)-propionamide; flk inhibitors | GRK2, GRK3, BLK | TSHR 395/4885POLB 3371/4885TDP1 2691/4885 |
| US-20210300940-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | TSHR 705/4885POLB 1480/4885TDP1 1084/4885 |
| US-20070213375-A1 | Triazole derivatives useful as Axl inhibitors | AXL, TYRO3, FLT3 | TSHR 94/4885POLB 4096/4885TDP1 1945/4885 |
| US-20080004273-A1 | Inhibitors of protein tyrosine kinase activity | HGF, ERBB2, MET | TSHR 1253/4885POLB 2206/4885TDP1 2357/4885 |
| US-20230113037-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | AHR, HRH4, HRH1 | TSHR 838/4885POLB 4033/4885TDP1 1588/4885 |
| US-20220135552-A1 | PYRROLE DERIVATIVES AS PLK1 INHIBITORS | PLK1, CDK1, AURKC | TSHR 542/4885POLB 483/4885TDP1 1975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.